Article summary
This week's edition of Life Sciences weekly highlights includes news about the British pharmaceutical industry’s strong criticism of the UK government’s proposals to increase the clawback rates in the Statutory Scheme currently under consultation requiring pharmaceutical companies to pay back a percentage from branded medicines sales to the government and points to last week’s report finding that there has been a 47% drop in foreign direct investment in UK life sciences as a consequence. Also included is news about an economic report on the cost savings that over-the-counter drugs save the NHS and patients, the EMA launching a consultation on a draft reflection paper for the use and regulation of AI and machine learning (ML) during a medicine’s lifecycle, the Commission releasing guidance on the transition of clinical trials compliance under the previous Directive 2001/20/EC to the new Clinical Trials Regulation, research organisations needing to comply with the UK HRA’s quality standards and design principles for participants by December 2023 and that Haleon topical pain...
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial